Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
Completed · Phase 3 · NCT03777657
Conditions: Gastric, or Gastroesophageal Junction Adenocarcinoma
At a glance
- Research payments reported, 2025
- $8,646
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 997
About the trial
- Sponsor
- BeiGene
- Tested
- Tislelizumab (drug), Placebo (drug), Cisplatin (drug), Oxaliplatin (drug), Capecitabine (drug), 5-Fluorouracil (drug)
- Dates
- Started 2018-12-13; completion 2024-08-27
- Results posted
- Yes
This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
From ClinicalTrials.gov, last updated 2025-02-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $8,646 in research payments for this study in 2025 (3 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fox Chase Cancer Center $8,646
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.